Evaluating the effects of BRIUMVI® on pregnancy outcomes in women with Multiple Sclerosis
Official title: BRIUMVI® Pregnancy Registry: A Prospective Study of Pregnancy and Infant Outcomes in Patients Treated With BRIUMVI®
Run by TG Therapeutics, Inc. · NCT06433765 · Data updated 2026-11-12
This study is trying to see if using BRIUMVI® during pregnancy affects the health of babies born to women with Multiple Sclerosis compared to those who didn’t use the medication.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 15 Years to 50 Years |
| Sex | Women only |
| Enrollment | 728 (estimated) |
| Sponsor | TG Therapeutics, Inc. Industry-sponsored |
| Locations | 1 site (Wilmington, North Carolina) |
| Status | Recruiting |
| Started | June 1, 2024 |
| Main results expected | March 31, 2035 |
| Study ends | March 31, 2035 |
| Registry record updated | October 29, 2026 |
| Trial ID | NCT06433765 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include pregnant women diagnosed with Multiple Sclerosis who have either been exposed to BRIUMVI® or have not been exposed during their pregnancy.
✕Probably not a fit
Patients who have been exposed to anti-CD20 monoclonal antibodies or known teratogens during pregnancy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to compare the prevalence of major congenital malformations in two groups of pregnant women with Multiple Sclerosis (MS): those who have been exposed to BRIUMVI® (Ublituximab) and those who have not. Participants must have a diagnosis of MS and be currently or recently pregnant. The study will collect data from a registry to assess the outcomes of pregnancies in these cohorts, focusing on the safety of BRIUMVI® during pregnancy.
Why it matters
Potential benefit: If successful, this study could provide critical insights into the safety of BRIUMVI® during pregnancy, potentially guiding treatment decisions for pregnant women with MS.
How similar studies have gone: While studies on the effects of medications during pregnancy are common, this specific evaluation of BRIUMVI® in pregnant women with MS is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. For exposed cohort: Participant exposed to at least 1 dose of BRIUMVI®. 2. For unexposed cohort: Participants not exposed to BRIUMVI® at any time during the pregnancy. 3. Diagnosis of MS. 4. Currently or recently (within 1 year of pregnancy outcome) pregnant. 5. Authorization from healthcare provider to provide data to registry. Exclusion Criteria: 1. Prior to enrollment, participant has exposure to anti-CD20 monoclonal antibodies at any time during pregnancy. 2. Occurrence of pregnancy outcome prior to first contact with the virtual research coordination center (VRCC) (retrospectively enrolled). 3. Exposure to known teratogens and/or investigational medications during pregnancy.
Where it's running
-
BRIUMVI® Pregnancy Registry Virtual Research Coordination Center
Wilmington, North Carolina, United States Recruiting
Study contacts
- Study coordinator: BRIUMVI® Pregnancy Registry Virtual Research Coordination Center
- Email: CRGBriumviPregnancyRegistry@thermofisher.com
- Phone: 1-877-411-4605
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treadmill-based virtual reality walking training for MS patients
This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.
-
Virtual Reality and Mental Practice to Improve Balance and Walking in Relapsing MS
This study tests whether virtual reality training or mental practice can improve balance and walking in people with relapsing–remitting multiple sclerosis.
-
REAL-MS: A Look at Autologous Stem Cell Transplant vs High-Efficacy MS Therapies in Real-World Care
This study tests how AHSCT compares to high-efficacy MS medicines in adults treated in routine clinical care.
-
Tolebrutinib in real-world MS care for patients treated by clinicians
This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.
-
Pilates via live video vs. prerecorded videos for people with multiple sclerosis
This study tests whether live, coach-led Pilates sessions through video calls are more beneficial than prerecorded Pilates videos for adults with MS.
-
Cooling During Inpatient Rehab for People with MS
This trial tests whether wearing a cooling vest during intensive training can reduce fatigue and improve walking, strength, balance, and cognition in people with multiple sclerosis during a 3-week inpatient rehab stay.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.